Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAS2R1 agonist (Amaro Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Amaro Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This preclinical-stage small molecule agonist, developed by **Amaro Therapeutics**, targets the **TAS2R1** receptor, a member of the bitter taste receptor family. While traditionally associated with oral taste perception, TAS2R1 is an extra-oral G-protein coupled receptor (GPCR) found in various tissues where it functions as part of the body's nutrient-sensing network. By activating TAS2R1, the compound aims to modulate metabolic and inflammatory pathways to restore homeostasis. The program is currently being investigated for the treatment of metabolic dysfunction and age-related inflammatory conditions, including **obesity**, **type 2 diabetes**, **metabolic-associated steatohepatitis (MASH)**, and other age-linked inflammatory disorders.
- Other names
- TAS2R1 agonistTAS-2R1 agonistTAS 2R1 agonist
02
Targets
TAS2R1 (Taste receptor type 2 member 1)
Beyond the preview
Go deeper on TAS2R1 agonist (Amaro Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAS2R1 agonist (Amaro Therapeutics).